Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2020 Sep 3:2020.09.01.20184101.
doi: 10.1101/2020.09.01.20184101.

Rapid 'mix and read' assay for scalable detection of SARS-CoV-2 antibodies in patient plasma

Hong Yue, Radosław P Nowak, Daan Overwijn, N Connor Payne, Stephanie Fischinger, Caroline Atyeo, Lindsey R Baden, Eric James Nilles, Elizabeth W Karlson, Xu G Yu, Jonathan Z Li, Galit Alter, Ralph Mazitschek, Eric S Fischer

Rapid 'mix and read' assay for scalable detection of SARS-CoV-2 antibodies in patient plasma

Hong Yue et al. medRxiv. .

Update in

  • Diagnostic TR-FRET assays for detection of antibodies in patient samples.
    Yue H, Nowak RP, Overwijn D, Payne NC, Fischinger S, Atyeo C, Lam EC, St Denis K, Brais LK, Konishi Y, Sklavenitis-Pistofidis R, Baden LR, Nilles EJ, Karlson EW, Yu XG, Li JZ, Woolley AE, Ghobrial IM, Meyerhardt JA, Balazs AB, Alter G, Mazitschek R, Fischer ES. Yue H, et al. Cell Rep Methods. 2023 Feb 20;3(3):100421. doi: 10.1016/j.crmeth.2023.100421. eCollection 2023 Mar 27. Cell Rep Methods. 2023. PMID: 37056371 Free PMC article.

Abstract

The human beta coronavirus SARS-CoV-2, causative virus of COVID-19, has infected more than 15 million people globally and continues to spread. Widespread, population level testing to detect active and past infections is critical to curb the COVID-19 pandemic. Antibody (serological) testing is the only option for detecting past infections outside the narrow window accessible to nucleic acid-based tests. However, currently available serological assays commonly lack scalability. Here, we describe the development of a rapid homogenous serological assay for the detection of antibodies to SARS-CoV-2 in patient plasma. We show that the fluorescence-based assay accurately detects seroconversion in COVID-19 patients from less than 1 microliter of plasma. Using a cohort of samples from COVID-19 infected or healthy individuals, we demonstrate detection with 100% sensitivity and specificity. This assay addresses an important need for a robust, low barrier to implementation, and scalable serological assay with complementary strengths to currently available serological platforms.

PubMed Disclaimer

Publication types

LinkOut - more resources